Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 6/20 | 0.58 |
| ▸ | IL1RN | P18510 | 5/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.53 |
| ▸ | GHSR | Q92847 | 7/20 | 0.52 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197039 | 0.92 | ERAP2 (0.61) | ERAP2IL1RNERAP1GHSRMMP2 | |
| SCHEMBL29691762 | 0.88 | ERAP2 (0.70) | ERAP2IL1RNERAP1GHSRMMP2 | |
| SCHEMBL31696808 | 0.87 | ERAP2 (0.64) | ERAP2IL1RNERAP1GHSRMMP1 | |
| SCHEMBL31720527 | 0.85 | ERAP2 (0.63) | ERAP2IL1RNERAP1GHSRMMP2 | |
| SCHEMBL30465909 | 0.84 | ERAP2 (0.70) | ERAP2IL1RNERAP1GHSRMMP2 | |
| SCHEMBL27869302 | 0.84 | ERAP2 (0.54) | ERAP2IL1RNERAP1GHSRMMP2 | |
| SCHEMBL30788023 | 0.84 | ERAP2 (0.63) | ERAP2IL1RNERAP1GHSRMMP2 | |
| SCHEMBL29684075 | 0.84 | ERAP2 (0.58) | ERAP2IL1RNERAP1GHSRKISS1R | |
| SCHEMBL31232500 | 0.83 | ERAP2 (0.63) | ERAP2IL1RNERAP1GHSR | |
| SCHEMBL30518838 | 0.83 | ERAP2 (0.61) | ERAP2IL1RNERAP1GHSRKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | ERAP2 638/4885IL1RN 546/4885ERAP1 262/4885 |
| US-20190070251-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | ERAP2 638/4885IL1RN 546/4885ERAP1 262/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | ERAP2 697/4885IL1RN 323/4885ERAP1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.